Imofinostat

Imofinostat
Clinical data
Other names	ABT-301; MPT-0E028; TSY-410
Identifiers
	IUPAC name (E)-3-[1-(benzenesulfonyl)-2,3-dihydroindol-5-yl]-N-hydroxyprop-2-enamide;
CAS Number	1338320-94-7;
PubChem CID	53464642;
ChemSpider	32701080;
UNII	T65L58FI65;
Chemical and physical data
Formula	C17H16N2O4S
Molar mass	344.39 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(C2=C1C=C(C=C2)/C=C/C(=O)NO)S(=O)(=O)C3=CC=CC=C3;
	InChI InChI=InChI=1S/C17H16N2O4S/c20-17(18-21)9-7-13-6-8-16-14(12-13)10-11-19(16)24(22,23)15-4-2-1-3-5-15/h1-9,12,21H,10-11H2,(H,18,20)/b9-7+; Key:MGTIFSBCGGAZDB-VQHVLOKHSA-N;

Imofinostat is an investigational new drug that is being developed by Formosa Pharmaceuticals and Anbogen Therapeutics for the treatment of colorectal cancer. It is a histone deacetylase inhibitor with selectivity for HDAC3.^[1]^[2]

References

↑ "Imofinostat". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
↑ Li CY, Wei CW, Tse KP, Huang SH, Yang TH, Lin MC, et al. (April 2026). "Imofinostat, a histone deacetylase inhibitor, enhances anti-tumoral activity on colorectal cancer with an immune checkpoint inhibitor". Cancer Research. 86 (7_Supplement) 4496. doi:10.1158/1538-7445.AM2026-4497.